Alumis
Los Angeles, California, United States · Biotechnology, Healthcare, Health Care · 200 employees
A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.
Funding history
- Funding Round — $40.0M — Jul 2024
- Funding Round — $129.5M — Mar 2024
- Series series c — $259.0M — Mar 2024
- Series series c — $259.0M — Mar 2024
- Series series c — $259.0M — Mar 2024
Recent signals
- Jan 02, 2026: Alumis Inc. Issues Claim for Indemnification Due to Breach by Climb Bio, Inc.
- Jan 02, 2026: SEC 8-K (8.01): On January 2, 2026, Alumis Inc. and its subsidiary Acelyrin, Inc. issued a Notice of Material Breach and Notification of Claim for Indemnification against Climb Bio, Inc. due to Climb Bio's refusal to pay a $3,000,000 Development Milestone payment that was due on January 1, 2026, as stipulated in the Asset Purchase Agreement dated January 11, 2024. This breach relates to a total potential obligation of $157.5 million that Climb Bio had agreed to pay to Acelyrin, contingent on achieving various milestones. The company is now seeking to enforce these financial obligations, which may impact their future collaborations and revenue projections.
- Jul 24, 2024: Raised $40.0M
- Mar 11, 2024: Raised $129.5M
- Mar 07, 2024: Raised $259.0M in Series series c
- Mar 07, 2024: Alumis Appoints New Executives
- Mar 07, 2024: Raised $259.0M in Series series c
- Mar 06, 2024: Raised $259.0M in Series series c
See plans & pricing → Track Alumis’s funding, hiring, and signals — with verified contacts — on Fundz.